Company news
Fate Therapeutics, Inc. news in 2024
Fate Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
December 8, 2024
Fate Therapeutics Announces Leadership Transition
November 28, 2024
Fate Therapeutics to Present at Upcoming December Investor Conferences
November 25, 2024
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
November 17, 2024
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 17, 2024
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 11, 2024
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 8, 2024
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
November 7, 2024
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 11, 2024
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 12, 2024
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
July 30, 2024
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2024
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 28, 2024
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 8, 2024
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 8, 2024
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 5, 2024
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 2, 2024
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 21, 2024
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 2, 2024
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 18, 2024
Fate Therapeutics to Present at Upcoming March Investor Conferences
February 29, 2024
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 25, 2024
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 7, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (May 2024)
Investor deck · 42 slides · May 2024